Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07051031
PHASE4

COVID-19 Reactogenicity

Sponsor: Marcel Curlin

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.

Official title: Reactogenicity, Patient Reported Outcomes and Vaccine Preference in Adults Immunized With Recombinant Protein or mRNA COVID-19 Vaccines

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2025-10-01

Completion Date

2026-06-14

Last Updated

2026-03-04

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Nuvaxovid (NVX-CoV2705)

COVID-19 vaccination

DRUG

mNEXSPIKE mRNA-1283

COVID-19 vaccination

Locations (1)

Oregon Health and Sciences University

Portland, Oregon, United States